曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MNKD 曼恩凯德生物医疗

交易中 05-04 12:26:32 EDT

2.81

-0.03

-1.23%

最高2.88	最低2.79	成交量124.67万
今开2.84	昨收2.84	日振幅3.35%
总市值8.66亿	流通市值8.44亿	总股本3.09亿
成交额353.05万	换手率0.41%	流通股本3.01亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MNKD","market":"US","secType":"STK","nameCN":"曼恩凯德生物医疗","latestPrice":2.805,"timestamp":1777911989632,"preClose":2.84,"halted":0,"volume":1246715,"delay":0,"changeRate":-0.012323943661971726,"floatShares":300981629,"shares":308795777,"eps":0.02,"marketStatus":"交易中","change":-0.035,"latestTime":"05-04 12:26:32 EDT","open":2.84,"high":2.88,"low":2.785,"amount":3530486.185165,"amplitude":0.033451,"askPrice":2.81,"askSize":5500,"bidPrice":2.8,"bidSize":9573,"shortable":3,"etf":0,"ttmEps":0.02,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777924800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1090987200000,"exchange":"NASDAQ","adjPreClose":2.84,"preHourTrading":{"tag":"盘前","latestPrice":2.83,"preClose":2.84,"latestTime":"09:29 EDT","volume":13583,"amount":38872.9880299,"timestamp":1777901399999,"change":-0.01,"changeRate":-0.003521,"amplitude":0.031303},"postHourTrading":{"tag":"盘后","latestPrice":2.84,"preClose":2.84,"latestTime":"19:52 EDT","volume":33927,"amount":96345.6957,"timestamp":1777679523205,"change":0,"changeRate":0,"amplitude":0.000106},"volumeRatio":0.723878,"impliedVol":0.9772,"impliedVolPercentile":0.8327},"requestUrl":"/m/hq/s/MNKD","defaultTab":"news","newsList":[{"id":"1195472595","title":"曼恩凯德生物医疗宣布首例患者加入Inhale-1St儿科研究，评估Afrezza®用于新诊断1型糖尿病青少年","url":"https://stock-news.laohu8.com/highlight/detail?id=1195472595","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195472595?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:10","pubTimestamp":1770635403,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，其Inhale-1St儿科研究项目已完成首例患者入组。该研究旨在评估吸入式胰岛素产品Afrezza®在新确诊1型糖尿病青少年群体中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148553929","title":"曼恩凯德宣布FDA批准更新Afrezza®标签，为从每日多次注射或胰岛素泵餐时治疗转换提供起始剂量指导","url":"https://stock-news.laohu8.com/highlight/detail?id=1148553929","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148553929?lang=zh_cn&edition=full","pubTime":"2026-01-26 19:06","pubTimestamp":1769425598,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，美国食品药品监督管理局已批准更新其吸入式胰岛素产品Afrezza®的药品标签。此次标签更新关键内容包括：为正在接受每日多次注射或胰岛素泵餐时治疗、并计划转换使用Afrezza®的患者，提供了明确的起始剂量指导方案。这一重要进展有望优化临床用药实践，为糖尿病患者提供更清晰、便捷的治疗转换路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144679814","title":"富国银行：美股“轧空行情”即将来临，这些股票或将迎来交易机会","url":"https://stock-news.laohu8.com/highlight/detail?id=1144679814","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144679814?lang=zh_cn&edition=full","pubTime":"2026-01-07 10:34","pubTimestamp":1767753273,"startTime":"0","endTime":"0","summary":"富国银行预计多重利好因素将推动美国股市上涨，尤其是那些被大量做空但表现滞后的股票。在周二发布的研究报告中，富国银行分析师Ohsung Kwon及其团队从罗素3000指数中筛选出一批被大量做空且表现落后、但有望即将反弹的股票。去年10月，美国银行在首次覆盖报告中给予Vera\"买入\"评级，目标价48美元。","market":"us","thumbnail":"https://community-static.tradeup.com/news/c76459198a96f48579b9be57b060ec45","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c76459198a96f48579b9be57b060ec45"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA","HRI","MTDR","MNKD","IR","CRGY","HASI","ENOV"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1172067255","title":"曼恩凯德生物医疗宣布美国FDA接受其Furoscix Readyflow™自动注射器的补充新药申请审查，针对慢性心力衰竭或慢性肾病成人水肿的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1172067255","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172067255?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:08","pubTimestamp":1764594489,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，美国FDA已接受其Furoscix Readyflow™自动注射器的补充新药申请审查，该药物用于治疗慢性心力衰竭或慢性肾病成人的水肿。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4584","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169320260","title":"曼恩凯德生物医疗股价在盘前交易中下跌5.7%，因公司决定中止肺病治疗的第三阶段临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1169320260","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169320260?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:15","pubTimestamp":1762780554,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗的股价在盘前交易中下跌5.7%，原因是公司宣布将中止针对肺病治疗的第三阶段临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197762624","title":"异动解读 | 曼恩凯德生物医疗盘前大跌6.93%，三期临床试验结果令人担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1197762624","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197762624?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:08","pubTimestamp":1762780104,"startTime":"0","endTime":"0","summary":"周一（11月10日）盘前，曼恩凯德生物医疗（MNKD）股价大跌6.93%，引发投资者关注。\n\n据悉，曼恩凯德生物医疗在其三期ICON-1临床试验中未观察到转化情况，这引发了市场对公司能否实现研究主要终点的担忧。这一消息对公司股价造成了明显的负面影响。\n\nICON-1试验是曼恩凯德生物医疗的一项重要研究，其结果可能对公司未来的药物开发和市场前景产生重大影响。未能观察到预期的转化情况意味着试验可能无法达到预设的主要终点，这可能会影响到新药的审批进程和公司的长期发展战略。投资者对这一不利消息反应强烈，导致公司股价在盘前交易中出现大幅下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128732960","title":"MannKind：在三期ICON-1试验中未观察到转化情况，因而对实现研究主要终点的可能性产生担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1128732960","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128732960?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:06","pubTimestamp":1762779992,"startTime":"0","endTime":"0","summary":"MannKind：在三期ICON-1试验中未观察到转化情况，因而对实现研究主要终点的可能性产生担忧","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNKD","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516548098","title":"曼恩凯德生物医疗2024财年实现净利润27.59百万美元，同比增加331.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548098","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516548098?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931288,"startTime":"0","endTime":"0","summary":"3月3日，曼恩凯德生物医疗公布财报，公告显示公司2024财年净利润为27.59百万美元，同比增加331.07%；其中营业收入为2.86亿美元，同比增加43.72%，每股基本收益为0.10美元。从资产负债表来看，曼恩凯德生物医疗总负债4.73亿美元，其中短期债务13.12百万美元，资产负债比为0.84，流动比率为0.04。机构评级：截至2025年3月3日，当前有7家机构对曼恩凯德生物医疗目标价做出预测，其中目标均价为10.00美元，其中最低目标价为9.00美元，最高目标价为12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000215abe4acf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000215abe4acf9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385666","title":"曼恩凯德生物医疗盘中异动 早盘股价大跌5.21%报5.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385666?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666711,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，曼恩凯德生物医疗股票出现异动，股价急速下挫5.21%。截至发稿，该股报5.19美元/股，成交量16.1874万股，换手率0.05%，振幅7.31%。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.06%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722315198951016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722315198951016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514585227","title":"曼恩凯德生物医疗盘中异动 股价大跌5.13%报5.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514585227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514585227?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:45","pubTimestamp":1740584740,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时45分，曼恩凯德生物医疗股票出现波动，股价快速下挫5.13%。截至发稿，该股报5.36美元/股，成交量90.4853万股，换手率0.33%，振幅4.51%。机构评级方面，在所有7家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.01%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226234540abddfef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226234540abddfef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508144336","title":"曼恩凯德生物医疗盘中异动 早盘急速跳水5.01%报5.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508144336?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:49","pubTimestamp":1738594187,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时49分，曼恩凯德生物医疗股票出现波动，股价急速跳水5.01%。截至发稿，该股报5.50美元/股，成交量45.284万股，换手率0.16%，振幅2.25%。最近的财报数据显示，该股实现营业收入70.08百万美元，净利润11.55百万美元，每股收益0.04美元，毛利52.06百万美元，市盈率69.00倍。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.34%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020322494798797234&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020322494798797234&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2495478508","title":"曼恩凯德生物医疗盘中异动 股价大跌5.06%报6.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2495478508","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495478508?lang=zh_cn&edition=full","pubTime":"2024-12-31 04:38","pubTimestamp":1735591125,"startTime":"0","endTime":"0","summary":"北京时间2024年12月31日04时38分，曼恩凯德生物医疗股票出现异动，股价急速下跌5.06%。截至发稿，该股报6.48美元/股，成交量151.569万股，换手率0.55%，振幅4.11%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为1.29%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231043845a20f77da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231043845a20f77da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492444009","title":"曼恩凯德生物医疗盘中异动 早盘股价大涨5.16%报6.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492444009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492444009?lang=zh_cn&edition=full","pubTime":"2024-12-20 22:37","pubTimestamp":1734705463,"startTime":"0","endTime":"0","summary":"北京时间2024年12月20日22时37分，曼恩凯德生物医疗股票出现波动，股价快速上涨5.16%。截至发稿，该股报6.63美元/股，成交量51.8372万股，换手率0.19%，振幅4.60%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.25%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220223743ab8767a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220223743ab8767a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492184919","title":"曼恩凯德生物医疗盘中异动 股价大涨5.06%报6.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492184919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492184919?lang=zh_cn&edition=full","pubTime":"2024-12-18 22:53","pubTimestamp":1734533614,"startTime":"0","endTime":"0","summary":"北京时间2024年12月18日22时53分，曼恩凯德生物医疗股票出现异动，股价快速上涨5.06%。截至发稿，该股报6.23美元/股，成交量52.322万股，换手率0.19%，振幅2.85%。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.48%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121822533595ea554e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121822533595ea554e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492965437","title":"曼恩凯德生物医疗盘中异动 股价大跌5.10%报5.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492965437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492965437?lang=zh_cn&edition=full","pubTime":"2024-12-17 22:43","pubTimestamp":1734446618,"startTime":"0","endTime":"0","summary":"北京时间2024年12月17日22时43分，曼恩凯德生物医疗股票出现异动，股价急速下跌5.10%。截至发稿，该股报5.95美元/股，成交量40.2456万股，换手率0.15%，振幅3.67%。最近的财报数据显示，该股实现营业收入70.08百万美元，净利润11.55百万美元，每股收益0.04美元，毛利52.06百万美元，市盈率74.88倍。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.56%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217224338984c908b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217224338984c908b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4584","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486015020","title":"曼恩凯德生物医疗盘中异动 快速下跌5.01%报6.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486015020","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486015020?lang=zh_cn&edition=full","pubTime":"2024-11-26 22:43","pubTimestamp":1732632215,"startTime":"0","endTime":"0","summary":"北京时间2024年11月26日22时43分，曼恩凯德生物医疗股票出现异动，股价大幅下挫5.01%。截至发稿，该股报6.38美元/股，成交量64.4772万股，换手率0.23%，振幅3.63%。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.50%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126224336abe0c251&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126224336abe0c251&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484104905","title":"曼恩凯德生物医疗2024财年第三财季实现净利润11.55百万美元，同比增加571.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484104905","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484104905?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:03","pubTimestamp":1731773000,"startTime":"0","endTime":"0","summary":"11月17日，曼恩凯德生物医疗公布财报，公告显示公司2024财年第三财季净利润为11.55百万美元，同比增加571.51%；其中营业收入为70.08百万美元，同比增加36.74%，每股基本收益为0.04美元。从资产负债表来看，曼恩凯德生物医疗总负债6.74亿美元，其中短期债务13.07百万美元，资产负债比为0.69，流动比率为0.05。机构评级：截至2024年11月17日，当前有5家机构对曼恩凯德生物医疗目标价做出预测，其中目标均价为9.40美元，其中最低目标价为7.00美元，最高目标价为12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000435a23e0722&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000435a23e0722&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483384721","title":"曼恩凯德生物医疗盘中异动 临近午盘快速上涨5.32%报7.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483384721","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483384721?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:55","pubTimestamp":1731603324,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日00时55分，曼恩凯德生物医疗股票出现异动，股价快速拉升5.32%。截至发稿，该股报7.33美元/股，成交量136.357万股，换手率0.49%，振幅5.89%。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.64%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115005525971a69c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115005525971a69c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MNKD","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481101760","title":"曼恩凯德生物医疗盘中异动 早盘股价大跌9.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481101760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481101760?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:32","pubTimestamp":1731076368,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日22时32分，曼恩凯德生物医疗股票出现波动，股价急速下挫9.42%。截至发稿，该股报6.69美元/股，成交量50.0499万股，换手率0.18%，振幅5.68%。机构评级方面，在所有4家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.42%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822324895bdef38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822324895bdef38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2478148734","title":"曼恩凯德生物医疗盘中异动 快速拉升5.20%报6.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478148734","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478148734?lang=zh_cn&edition=full","pubTime":"2024-10-28 22:44","pubTimestamp":1730126676,"startTime":"0","endTime":"0","summary":"北京时间2024年10月28日22时44分，曼恩凯德生物医疗股票出现异动，股价急速拉升5.20%。截至发稿，该股报6.88美元/股，成交量50.734万股，换手率0.18%，振幅4.20%。机构评级方面，在所有4家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.58%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028224437ab7becba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028224437ab7becba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mannkindcorp.com","stockEarnings":[{"period":"1week","weight":0.0519},{"period":"1month","weight":0.1181},{"period":"3month","weight":-0.5087},{"period":"6month","weight":-0.4919},{"period":"1year","weight":-0.4263},{"period":"ytd","weight":-0.4991}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mannkind Corporation于1991年2月14日在美国特拉华州注册成立。Mannkind Corporation是一家生物制药公司，侧重于诸如糖尿病和癌症之类疗法和药品的开发、研制和推广。该公司的主导候选产品——AFREZZA吸入粉末，是一种超速效胰岛素，处于后期临床研究阶段，用于成人1型或2型糖尿病高血糖的控制治疗。AFREZZA是由该公司的专有技术圈颗粒加载到胰岛素分子里。这些加载的粒子雾化吸入后，会深入到使用AFREZZA吸入器的肺部。糖尿病是一个重大的健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.681818,"avgChangeRate":0.037571},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.027316},{"month":3,"riseRate":0.409091,"avgChangeRate":-0.021457},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.018416},{"month":5,"riseRate":0.545455,"avgChangeRate":0.101726},{"month":6,"riseRate":0.52381,"avgChangeRate":0.055192},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.056921},{"month":8,"riseRate":0.454545,"avgChangeRate":0.016248},{"month":9,"riseRate":0.681818,"avgChangeRate":0.078908},{"month":10,"riseRate":0.5,"avgChangeRate":-0.035124},{"month":11,"riseRate":0.409091,"avgChangeRate":0.019784},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.013619}],"exchange":"NASDAQ","name":"曼恩凯德生物医疗","nameEN":"MannKind"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供曼恩凯德生物医疗(MNKD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"曼恩凯德生物医疗,MNKD,曼恩凯德生物医疗股票,曼恩凯德生物医疗股票老虎,曼恩凯德生物医疗股票老虎国际,曼恩凯德生物医疗行情,曼恩凯德生物医疗股票行情,曼恩凯德生物医疗股价,曼恩凯德生物医疗股市,曼恩凯德生物医疗股票价格,曼恩凯德生物医疗股票交易,曼恩凯德生物医疗股票购买,曼恩凯德生物医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供曼恩凯德生物医疗(MNKD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}